Regeneron Pharmaceuticals Inc. expanded its nonexclusive deal with Astellas Pharma Inc. through 2023 in exchange for $165 million up front, bringing total committed funding stemming from licenses to its VelocImmune mouse antibody platform to roughly $2 billion. (BioWorld Today) Read More
